IL111134A - Immunological tolerance-inducing composition comprising a mucosa-binding molecule linked to a specific self-antigen/tolerogen - Google Patents

Immunological tolerance-inducing composition comprising a mucosa-binding molecule linked to a specific self-antigen/tolerogen

Info

Publication number
IL111134A
IL111134A IL11113494A IL11113494A IL111134A IL 111134 A IL111134 A IL 111134A IL 11113494 A IL11113494 A IL 11113494A IL 11113494 A IL11113494 A IL 11113494A IL 111134 A IL111134 A IL 111134A
Authority
IL
Israel
Prior art keywords
immunological tolerance
mucosa
tolerogen
binding molecule
antigen
Prior art date
Application number
IL11113494A
Other languages
English (en)
Other versions
IL111134A0 (en
Original Assignee
Duotol Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9303301A external-priority patent/SE9303301L/xx
Application filed by Duotol Ab filed Critical Duotol Ab
Publication of IL111134A0 publication Critical patent/IL111134A0/xx
Publication of IL111134A publication Critical patent/IL111134A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11113494A 1993-10-08 1994-10-03 Immunological tolerance-inducing composition comprising a mucosa-binding molecule linked to a specific self-antigen/tolerogen IL111134A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9303301A SE9303301L (sv) 1993-10-08 1993-10-08 Medel som inducerar immunologisk tolerans
US16010693A 1993-11-30 1993-11-30
US08/184,458 US5681571A (en) 1993-10-08 1994-01-19 Immunological tolerance-inducing agent

Publications (2)

Publication Number Publication Date
IL111134A0 IL111134A0 (en) 1994-12-29
IL111134A true IL111134A (en) 2000-06-01

Family

ID=27355731

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11113494A IL111134A (en) 1993-10-08 1994-10-03 Immunological tolerance-inducing composition comprising a mucosa-binding molecule linked to a specific self-antigen/tolerogen

Country Status (13)

Country Link
US (2) US5681571A (de)
EP (1) EP0722340B1 (de)
JP (1) JP4447657B2 (de)
KR (1) KR100445547B1 (de)
CN (1) CN1079677C (de)
AT (1) ATE165515T1 (de)
AU (1) AU689138B2 (de)
CA (1) CA2173254C (de)
DE (1) DE69409962T2 (de)
DK (1) DK0722340T3 (de)
ES (1) ES2120073T3 (de)
IL (1) IL111134A (de)
WO (1) WO1995010301A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US20010036917A1 (en) 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
EP0840796A2 (de) * 1995-07-26 1998-05-13 Maxim Pharmaceuticals Mukosale abgabe von polynukleotiden
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
WO1997028817A1 (en) * 1996-02-09 1997-08-14 Cheng Pi Wan Receptor ligand-facilitated delivery of biologically active molecules
CA2252790A1 (en) * 1997-02-28 1998-09-03 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (sidr)
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
WO1998057655A1 (en) * 1997-06-17 1998-12-23 Immunex Corporation A method of enhancing antigen-specific peripheral immune tolerance
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US20050241024A1 (en) * 1997-10-07 2005-10-27 Langridge William H Transgenic plant-based vaccines
US20050186219A1 (en) * 1997-10-07 2005-08-25 Langridge William H. Transgenic plant-based vaccines
US6777546B2 (en) * 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
US7422747B2 (en) * 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
AU3179999A (en) 1997-12-16 1999-07-05 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
GB9800487D0 (en) * 1998-01-09 1998-03-04 Oratol Limited Therapies
WO1999057152A1 (en) 1998-05-07 1999-11-11 Research Corporation Technologies, Inc. Oral administration of immunoglobulins for treating autoimmune hearing loss
KR20010043441A (ko) * 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 백신용 면역조절제
US6171802B1 (en) * 1998-06-10 2001-01-09 Kent State University Detection and amplification of ligands
US20020052002A1 (en) * 1998-06-10 2002-05-02 Niehaus Gary D. Detection and amplification of ligands
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
EP1254156A4 (de) * 2000-01-27 2003-05-21 Univ Loma Linda Auf transgene pflanzen basierender impstoff
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
MXPA04003156A (es) * 2001-10-04 2005-01-25 Protein Therapeutics Inc El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes .
US20090304733A1 (en) * 2004-07-28 2009-12-10 Jacob Pitcovski Vaccine comprising recombinant ct or lt toxin
EP1874334A4 (de) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd Zusammensetzungen mit von beta 2-glykoprotein i stammenden peptiden zur prävention und/oder behandlung von gefässerkrankungen
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US9518087B2 (en) * 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP3909603A1 (de) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting-therapeutika
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532850B1 (fr) * 1982-09-15 1985-12-20 Pasteur Institut Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
ATE99331T1 (de) * 1989-09-08 1994-01-15 Takeda Chemical Industries Ltd Fusionsproteine und herstellung davon.
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins

Also Published As

Publication number Publication date
AU7867194A (en) 1995-05-04
CA2173254A1 (en) 1995-04-20
DK0722340T3 (da) 1999-02-22
US6322796B1 (en) 2001-11-27
AU689138B2 (en) 1998-03-26
IL111134A0 (en) 1994-12-29
DE69409962D1 (de) 1998-06-04
WO1995010301A1 (en) 1995-04-20
CN1079677C (zh) 2002-02-27
EP0722340A1 (de) 1996-07-24
CN1135182A (zh) 1996-11-06
US5681571A (en) 1997-10-28
ATE165515T1 (de) 1998-05-15
EP0722340B1 (de) 1998-04-29
JPH09503520A (ja) 1997-04-08
DE69409962T2 (de) 1998-08-27
KR960704573A (ko) 1996-10-09
CA2173254C (en) 2005-09-13
ES2120073T3 (es) 1998-10-16
JP4447657B2 (ja) 2010-04-07
KR100445547B1 (ko) 2004-11-20

Similar Documents

Publication Publication Date Title
IL111134A (en) Immunological tolerance-inducing composition comprising a mucosa-binding molecule linked to a specific self-antigen/tolerogen
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
MX9302199A (es) Aditivo para vacuna.
EP0306524A4 (de) Von antikörpern, die unter verwendung eines eine beschränkte anzahl von antigenen präsentierenden pathogenen agens oder eines seiner derivate hergestellt worden sind, erkannte antigene determinanten.
EP0362279A4 (de) Saponin-hilfsmittel.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
FI932561A (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
GR3031716T3 (en) Immunogens against gonadotropin releasing hormone
EP0359063A3 (en) Antibody having high affinity to hapten as antigen and immunogen for obtaining the same
NZ209635A (en) Pharmaceutical composition containing extract from microorganism and detoxified endotoxin
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
ES483374A1 (es) Procedimiento para modificar las propiedades antigenas de unantigeno de polen de la hierba
ES8401722A1 (es) Procedimiento de obtencion de vacunas contra el patogeno h influenzae tipo b.
DK0831881T3 (da) CETP til forøgelse af HDL-cholesterolniveau
EP0589348A3 (de) Verfahren zur immunchemischen Quantifizierung von inaktivierten, immunreaktiven Antigenen.
GB2147806B (en) Refined detoxified endotoxin compositions
HUT46236A (en) Process for producing and utilizing antigenes of treponema hyodysenteriae
GB2144129B (en) Antigens as immunostimulant adjuvants
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
栗原英見 Humoral immune response to an antigen from Porphyromonas gingivalis 381 in periodontal disease
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.
IT8721792A0 (it) Metodo per la immunolocalizzazione di antigeni con l'impiego di anticorpi diretti contro epitopi di natura non glucidica
IT1158020B (it) Metodologia per la preparazione dell'antigene toxotossina adsorbito su emazie di montone
DE59704477D1 (de) Pharmazeutische antigen-/antikörperpräparation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees